'Catching the wave - How to take advantage of the rising tide in biotech finance'
A roundtable discussion Organized by Karolinska Institutet, the Unit for Bioentrepreneurship, Stockholm Bioregion and Science Business Publishing With the support of TVM Capital
Investor-company networking opportunity | 13 June, 2006. Stockholm
With the support of TVM Capital and Stockholm BioRegion
The financing market for biotech companies in Europe has been showing signs of life lately - with more private fundings, IPOs and trade sales. Latest data suggest 2005 was the best year for financing in the history of the European biotech industry in Europe, save for the bubble year of 2000. In fact, for the first time in the 30-year history of the sector, there were more public offerings in Europe, with 23 IPOs, than in the U.S., with 13, according to a recent report by Ernst & Young. The strength of the European market was further highlighted in May, when Astra Zeneca announced a surprise bid for Cambridge Antibody Technologies.
So how to take advantage of that trend - and will it continue?
That is the subject of an unusual roundtable discussion being organized by Karolinska Institutet, the famed medical university that names the Nobel Prize in Physiology or Medicine; its Unit for Bioentrepreneurship; Stockholm BioRegion; and Science|Business, a news service that covers early-stage investment in R&D.
For a report on the meeting, click here.
Discussion topics
- The biotech financing market - what's hot and why?
- Will the money keep flowing?
- VC, IPO or trade sale - which financing route works best?
- What do investors want? What do the bio/pharma majors want?
